Cargando…

An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects

INTRODUCTION: Hyporesponsiveness to recombinant human erythropoietin (rhEPO) is a major problem affecting some patients with chronic kidney disease (CKD), predominantly those on hemodialysis (HD). Daprodustat (GSK1278863) is a hypoxia-inducible factor prolyl hydroxylase inhibitor that is being inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cizman, Borut, Sykes, Andy P., Paul, Gitanjali, Zeig, Steven, Cobitz, Alexander R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035126/ https://www.ncbi.nlm.nih.gov/pubmed/29989040 http://dx.doi.org/10.1016/j.ekir.2018.02.009

Ejemplares similares

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023)

The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects
por: Caltabiano, Stephen, et al.
Publicado: (2018)

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease
por: Holdstock, Louis, et al.
Publicado: (2018)

Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure
por: Caltabiano, Stephen, et al.
Publicado: (2019)

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
por: Meadowcroft, Amy M, et al.
Publicado: (2018)

Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients
por: Kanai, Hidetoshi, et al.
Publicado: (2021)

Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function
por: Mahar, Kelly M., et al.
Publicado: (2022)

Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial
por: Singh, Ajay K., et al.
Publicado: (2022)

Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients
por: Sibbel, Scott P., et al.
Publicado: (2015)

Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2022)

“Trace” the Element: The Plausible Role Played by Selenium in the Erythropoietin Hyporesponsiveness
por: Azancot, Sarah, et al.
Publicado: (2022)

Daprodustat: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
por: Joharapurkar, Amit A., et al.
Publicado: (2022)

Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
por: Cizman, Borut, et al.
Publicado: (2020)

A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis
por: Bailey, Christine K., et al.
Publicado: (2019)

The Predictive Parameters of Erythropoietin Hyporesponsiveness in Patients on Continuous Ambulatory Peritoneal Dialysis
por: Kim, Jeong Ki, et al.
Publicado: (2001)

Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination
por: Mahar, Kelly M., et al.
Publicado: (2021)

Cardiovascular Event Rates Among Hemodialysis Patients Across Geographical Regions—A Snapshot From The Dialysis Outcomes and Practice Patterns Study (DOPPS)
por: Stirnadel-Farrant, Heide A., et al.
Publicado: (2019)

Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report
por: Yu, Wei-Hong, et al.
Publicado: (2020)

Anemia and mortality in patients with nondialysis-dependent chronic kidney disease
por: Stirnadel-Farrant, Heide A., et al.
Publicado: (2018)

Factors Influencing Aspirin Hyporesponsiveness in Elderly Chinese Patients
por: Ou, Wei mei, et al.
Publicado: (2019)

Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional Study
por: Hara, Takashi, et al.
Publicado: (2015)

Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
por: Ishii, Taisuke, et al.
Publicado: (2021)

Daprodustat: A potential game-changer in renal anemia therapy—A perspective
por: Haider, Muhammad Usman, et al.
Publicado: (2023)

An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat
por: Becker, Kimberly A., et al.
Publicado: (2017)

Daprodustat Accelerates High Phosphate-Induced Calcification Through the Activation of HIF-1 Signaling
por: Tóth, Andrea, et al.
Publicado: (2022)

Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study
por: Iso, Takashi, et al.
Publicado: (2022)

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020)

Hypotonic-hyporesponsive Episodes After Diphtheria, Tetanus and Acellular Pertussis Vaccination
por: Hansen, John, et al.
Publicado: (2021)

Ionomycin Treatment Renders NK Cells Hyporesponsive
por: Romera-Cárdenas, Gema, et al.
Publicado: (2016)

NK Cell Hyporesponsiveness: More Is Not Always Better
por: Frutoso, Marie, et al.
Publicado: (2019)

Immunological hyporesponsiveness in tuberculosis: The role of mycobacterial glycolipids
por: Correia-Neves, Margarida, et al.
Publicado: (2022)

Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis
por: Kobayashi, Shizuka, et al.
Publicado: (2022)

Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy
por: Kropf, Pascale, et al.
Publicado: (2007)

Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity
por: Maggi, Jaxaira, et al.
Publicado: (2015)

Brainstem white matter microstructure is associated with hyporesponsiveness and overall sensory features in autistic children
por: Surgent, Olivia, et al.
Publicado: (2022)

Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
por: Zheng, Qiyan, et al.
Publicado: (2021)

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
por: Sharma, Rakesh K, et al.
Publicado: (2009)

Redox Balance Alterations and Hyporesponsiveness of Synovial T Cells in Rheumatoid Arthritis
por: Breedveld, Ferdinand C, et al.
Publicado: (2000)

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5e2kpn4s8dpuhqmpak8u8at510